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Activation of the HGF-Met pathway evokes dynamic biological responses that support the 
morphogenesis, regeneration and survival of cells and tissues. A characterization of 
conditional Met knockout mice indicates that the HGF-Met pathway plays important roles in 
the regeneration, protection and homeostasis of cells such as hepatocytes, renal tubular cells, 
and neurons. Preclinical studies in disease models have indicated that recombinant HGF 
protein and expression plasmid for HGF are biological drug candidates for the treatment of 
patients with diseases or injuries that involve impaired tissue function. The phase-I and 
phase-I/II clinical trials of the intrathecal administration of HGF protein for the treatment of 
patients with amyotrophic lateral sclerosis and spinal cord injury, respectively, are ongoing. 
Biological actions of HGF that promote the dynamic movement, morphogenesis and survival of 
cells also closely participate in invasion-metastasis and resistance to the molecular-targeted 
drugs in tumor cells. Different types of HGF-Met pathway inhibitors are now in clinical trials 
for treatment of malignant tumors. Basic research on HGF and Met has lead to drug discoveries 
in regenerative medicine and tumor biology. 
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Two-Pronged Physiological Roles 
 
 Growth factors and their receptors play definitive roles in the development, regeneration 
and homeostasis of tissues. Aberrant regulation of the growth factor signaling in both positive 
and negative directions participates in the onset and progression of diseases and pathology. 
Based on the physiological and pathological significance of growth factors, both they and 
their receptors have been targets in drug discovery and development. Selective inhibitors 
against ligand growth factors, and their growth factor receptors, are currently indispensable in 
the molecular targeted therapy of malignant tumors. 
 Hepatocyte growth factor (HGF) was molecularly cloned as a mitogenic protein for 
hepatocytes (1, 2). The promotion of hepatocyte replication by HGF, and the increase in HGF 
levels following liver injury indicated its role in liver regeneration. Independently, the scatter 
factor, originally identified as a fibroblast-derived cell motility factor for epithelial cells, was 
shown to be an identical molecule to HGF (3). In 1991, the receptor for HGF was identified 
as a c-met proto-oncogene product of transmembrane receptor tyrosine kinase (4, 5). These 
early findings indicated the biological and physiological roles for HGF and Met in liver 
regeneration, tumorigenesis, and tumor invasion. 
 Characteristic biological responses that are driven by the HGF-Met receptor pathway 
include the dynamic movement, morphogenesis and survival of cells. The induction of 
epithelial branching tubulogenesis for renal tubular cells in a 3-dimensional collagen matrix 
by HGF had a particular impact, because HGF was the first of the growth factors and 
bioactive molecules to induce epithelial tubulogenesis/morphogenesis (6). Impairment in both 
the survival of hepatic progenitor cells and in the migration of myogenic precursor cells that 
is seen in the conventional knockout of Met gene in mice indicates potent actions of the 
HGF-Met pathway in dynamic migration and promotion of cell survival. Based on studies in 
the tissue-specific disruption of Met gene and the efficacy of HGF in preclinical disease 
models, recombinant HGF protein and HGF gene have become biological drug candidates for 
the treatment of patients with diseases that involve impaired tissue function (7). Conversely, 
the induction of dynamic 3-dimensional morphogenesis and migration and the promotion of 
cell survival by HGF also are the biological basis for the invasion and survival, respectively, 
of tumor cells. Activation of the HGF-Met pathway closely participates not only in tumor 
development, tumor invasion and metastasis but also in resistance to anticancer therapies (Fig. 
1). Therefore, the development of drugs that inhibit the HGF-Met pathway has gained much 
attention in anticancer drug development (8−10).  
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Interaction between HGF and Met 
 
 HGF is a heterodimeric molecule composed of an α-chain and a β-chain, which are 
linked by one disulfide bridge (Fig. 2A). The α-chain contains 4 kringle domains, while the 
β-chain contains a serine protease-like structure (1, 2). HGF is secreted as a single-chain 
precursor HGF and the extracellular processing into a two-chain mature HGF is coupled to 
the activation of HGF. Serine proteases such as HGF-activator and matriptase are responsible 
for the processing of HGF (11). The Met receptor is composed of structural domains that 
include the extracellular Sema, PSI (a similar structure is found in the plexins, semaphorins 
and integrins) and IPT (a similar structure is found in the immunoglobulin-like fold shared by 
plexins and transcriptional factor) domains, the transmembrane domain, the intracellular 
juxtamembrane, and the tyrosine kinase domains. The Sema domain serves as a key element 
for ligand binding (12), while the involvement of IPT-3 and IPT-4 in the binding to HGF has 
been demonstrated by another approach (13). 
 HGF binds to Met through two different mechanisms: the α-chain binds with high affinity 
while the β-chain binds with low affinity. In the α-chain, the NK1 (the N-terminal and first 
kringle domains) of HGF provides a high-affinity binding site for Met. The α-chain alone 
exhibits high-affinity binding to Met, whereas the binding of the α-chain does not activate 
Met (14). When Met is occupied by the α-chain, the low-affinity binding of the β-chain 
induces the activation of Met and of biological responses. Hence, the α-chain is a 
high-affinity binding module to Met, while the β-chain is an activation module for Met, as 
well as a low-affinity binding module to Met. The structure of the extracellular complex 
between HGF and Met was proposed using structural analyses such as small-angle X-ray 
scattering (Fig. 2A) (12). In this structure model, two HGF molecules form the dimer, 
wherein NK1 domains provide a dimerization module for the HGF-Met heterotetramer 
complex. The structure of the complex between the β-chain of HGF and the Sema-PSI 
domains of Met was revealed by crystallographic analysis (Fig. 2B) (15, 16). 
 The Met tyrosine kinase domain follows a conserved bilobal protein kinase architecture 
with an N-terminal, β-sheet-containing domain linked through a hinge segment to the 
α-helical C lobe (Fig. 2C) (17, 18). A characteristic feature of Met is the presence of the 
C-terminal tail that contains tyrosine residues (1349YVHVNAT1356YVNV). The binding of 
HGF to the extracellular region of Met results in the receptor phosphorylation of multiple 
tyrosine residues within the cytoplasmic region. The phosphorylation of Tyr1234 and Tyr1235 
within the tyrosine kinase domain positively regulates the catalytic activity of tyrosine kinase. 
The phosphorylation of C-terminal tyrosine residues Tyr1349 and Tyr1356 recruits 
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intracellular signaling molecules, including PI3K (phosphatidylinositol 3-kinase), Grb2 
(growth-factor-receptor-bound protein 2), Gab1 (Grb2-associated binder 1), PLCγ 
(phospholipase Cγ), and Shp2 (SH2-domain-containing protein tyrosine phosphatase 2). Gab1 
is the most crucial substrate and adapter for the HGF-Met pathway, and the direct interaction 
of Gab1 with tyrosine phosphorylated Met is mediated by the Met-binding sequence in Gab1 
(19). 
 The cytoplasmic juxtamembrane domain, which is composed of 47 highly conserved 
amino acids, acts as a negative regulator in terms of Met-dependent signal transduction. Cbl, 
an E3 ubiquitin ligase, binds the phosphorylated Y1003 of Met, and this Cbl binding results in 
Met ubiquitination, endocytosis and transport to the endosomal compartment, followed by 
degradation (20). Cbl-mediated degradation of the activated Met provides a mechanism that 
either attenuates or terminates Met-mediated signaling. Phosphorylation of Ser985 in the 
juxtamembrane domain regulates the activation status of Met upon HGF stimulation. 
Met-Ser985 is phosphorylated by protein kinase-C and is dephosphorylated by protein 
phosphatase-2A (21). In normal hepatocytes, HGF-dependent Met activation and mitogenesis 
were suppressed when Met-Ser985 was phosphorylated. In mice, Met-Ser985 
phosphorylation was decreased after liver injury and was reciprocally associated with Met 
activation during liver regeneration. The phosphorylation of Met-Ser985 plays a regulatory 
role in Met activation in response to quiescence, injury and regeneration. (22). 
 
Tissue Regeneration, Protection and Homeostasis Deduced from Met Disruption 
 
 The knockout mice of the HGF or Met gene in the whole body are lethal in the 
embryonic stage due to the impairment of organogenesis in the placenta and liver (23, 24). 
Moreover, HGF provides spatially defined chemoattractant-like motogenic signals for 
myogenic precursor cells—the migration of myogenic precursor cells from dermo-myotome 
in the somite to limb buds and the diaphragm is impaired in Met-/- mice, which causes 
deformed skeletal muscles of the limb and diaphragm in mutant mice (25). These studies in 
conventional knockout mice have provided the biological roles of HGF and Met during 
embryonic development. On the other hand, characterizations of conditional Met knockout 
mice have indicated that the HGF-Met pathway plays important roles in regeneration, 
protection and homeostasis in various cells and tissues (Table 1). 
 Hepatocytes subjected to selective loss of the functional Met are highly susceptible to cell 
death even after mild liver injury, indicating that anti-apoptotic activity of HGF plays a role in 
protecting the liver (26). Liver- or hepatocyte-specific Met-/- mice show delayed liver 
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regeneration associated with persistent inflammatory reaction (28). Activation of Met plays a 
role in the persistence of Erk1/2 activation and in the regulation of the G2/M gene expression 
program throughout liver regeneration following partial hepatectomy (27). In addition to 
regenerative responses in mature hepatocytes, HGF-Met signaling supports the in vitro sphere 
formation of hepatic stem cells (oval cells) and in vivo hepatic stem cell-mediated 
regeneration (32). Met-deficient oval cells were more prone to apoptosis when exposed to 
proapoptotic conditions. After bile duct ligation, hepatocyte-specific Met-/- mice were more 
susceptible to chronic inflammation and fibrotic change compared with control mice (30). 
The effects shown by these liver- or hepatocyte-specific Met-/- mice indicate the physiological 
roles of the HGF-Met pathway in the protection, regeneration, anti-inflammation, and 
anti-fibrosis of the liver. Thus, HGF seems to be a hepatotrophic factor that plays a major role 
in liver regeneration. 
 Loss of functional Met in renal tubules led to no appreciable defect in renal function. 
However, the tubular cell-specific Met-/- mice displayed higher serum creatinine, more severe 
morphologic lesions, and increased apoptosis, compared to control mice when both were 
subjected to renal injury (33). In podocyte-specific Met-/- mice, no pathology was seen, 
whereas, the mice developed more severe podocyte apoptosis and albuminurea in comparison 
with control mice, when both were subjected to toxic renal injury for podocytes (34). 
Collecting duct-selective Met dysfunction indicated that there were trends toward increased 
interstitial fibrosis, infiltration of the interstitium, and acute tubular necrosis following a 
unilateral obstruction, and there was a reduced regenerative response after the release from 
the obstruction (35). 
 Disruption of the Met gene in epidermal keratinocytes demonstrated an indispensable role 
for the HGF-Met pathway in skin wound healing (37). Because the migration of keratinocytes 
post-wounding was almost completely impaired in Met-/- keratinocytes, re-epithelialization 
was severely suppressed. Wound closure occurred exclusively in a few keratinocytes that had 
escaped recombination, indicating that the skin wound process selected and amplified residual 
cells that express a functional Met. These results indicated a definitive role for the HGF-Met 
pathway in skin wound healing. In mice with Met-deficient dendritic cells, those cells failed 
to reach skin-draining lymph nodes upon activation while exhibiting an activated phenotype, 
and the contact hypersensitivity reactions in response to contact allergens were significantly 
impaired (44). HGF-Met signaling in cutaneous dendritic cells may play a critical role in 
maintaining normal immune function. 
 Conditional knockout mice with selective disruption of Met gene in pancreatic β-cells 
displayed significantly diminished glucose tolerance and reduced plasma insulin after a 
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glucose challenge (39). In vitro glucose-stimulated insulin secretion in the islets from 
β-cell-Met-/- mice was decreased by ~50% compared with control islets. These changes in 
β-cell function in the conditional Met knockout mice were not accompanied by changes in total 
β-cell mass, islet morphology, or β-cell proliferation (39). Another group using β-cell-Met-/- 
mice displayed mild hyperglycemia and a complete loss of acute-phase insulin secretion in 
response to glucose (38). Therefore, HGF-Met signaling in the β-cell is not essential for β-cell 
growth, but it is essential for normal glucose-dependent insulin secretion and glucose 
homeostasis. 
 A number of allelic or copy variants of the Met gene have been associated with 
autism-spectrum disorders (45). One variant reduced Met promoter activity, implicating 
reduced Met gene expression in autism susceptibility (46). Conditional Met deletion in dorsal 
pallially derived forebrain neurons in mice demonstrated changes in dendrite and dendritic 
spine morphology in forebrain neurons (41), as well as circuit-specific intracortical 
hyperconnectivity (42). These studies demonstrated the contribution of Met signaling to the 
establishment of proper circuit function in the neocortex, which is potentially relevant to 
autism-spectrum disorders. 
 Collectively, tissue-specific disruption of the functional Met in mice indicated that HGF 
plays a promoting role in the regeneration, protection, and homeostasis of tissues, but an 
inhibitory role that can progress to chronic inflammation and fibrosis. Thus, enhancement or 
proper regulation of Met-mediated signaling and biological responses is likely to be 
therapeutic for the treatment of different types of diseases. 
 
HGF as a Biological Drug Candidate 
 Therapeutic actions and their mechanisms have been studied in a variety of disease 
models in experimental animals (7). Here, the clinical studies, and development of 
recombinant HGF protein and HGF gene as drug candidates are described. 
 
Chronic leg ulcer 
 Chronic leg ulcer treatment in elderly patients is a widespread healthcare problem. 
Chronic leg ulcers can result from different causes, such as diabetes and/or inappropriate 
circulation, and can be very difficult to heal. Involvement of the HGF-Met pathway in the 
pathophysiology of chronic leg ulcer might be considered by evaluating the status of Met 
activation in tissues with pathology. In clinical studies focused on cutaneous healing and 
non-healing wounds, the phosphorylation of Met was most prominent in keratinocytes and 
dermal cells in normally healing wounds. However, the tyrosine phosphorylation of Met was 
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barely detectable in non-healing wounds, which suggested reduced Met activation (47). 
 It is notable that the disruption of functional Met in epidermal keratinocytes indicated 
that Met-deficient keratinocytes were unable to contribute to the re-epithelialization of skin 
wounds in mice (37). Therefore, activation of the HGF-Met pathway is essential for a 
fundamental regenerative process during skin wound healing and may not be substituted for 
by other bioactive molecules for the generation of hyperproliferative epithelium in skin. In a 
full-thickness cutaneous excision model in diabetic mice, the topical administration of 
recombinant HGF protein promoted angiogenesis, extracellular matrix remodeling, 
re-epithelialization, and wound closure (48, 49). 
 The first clinical study using recombinant human HGF protein was done to investigate 
the physiological and therapeutic effects of HGF on chronic leg ulcers. HGF in gel form was 
locally applied to chronic leg ulcers in 11 patients (50). This pilot study demonstrated 
excellent (84–100% area reduction) or partial healing (58–59%) in eight out of 11 patients. 
The microcirculatory perfusion was significantly correlated to the reduction of ulcerous areas 
in the treated ulcers. This study suggests that the topical application of HGF protein may 
facilitate the healing of chronic leg ulcers, possibly by improving microcirculation. Because 
no control group was included in this pilot study, proper control studies must be performed 
for definitive clinical evaluation. 
 
Critical limb ischemia and HGF gene drugs 
 Critical limb ischemia is the most severe form of peripheral arterial disease due to 
atherosclerosis, and is a common clinical problem that has no effective medical therapy. The 
standard therapy for critical limb ischemia remains to be either lower-extremity 
revascularization through open bypass surgery or by endovascular techniques, or 
lower-extremity amputation when revascularization is not an option. Obviously, there is great 
need for less-invasive therapies to improve limb perfusion in patients with critical limb 
ischemia. 
 Met receptor is expressed in different types of vascular endothelial cells, and HGF 
stimulates the migration and motility of different types of endothelial cells (51−53). Further 
studies have indicated that HGF supports angiogenesis through multiple mechanisms, 
targeting not only endothelial cells but also endothelial progenitor cells. In preclinical animal 
models for limb ischemia, the intramuscle administration of recombinant HGF protein or 
expression plasmid for HGF facilitated collateral new vessel formation, improved blood flow, 
and reduced muscle atrophy (55, 56). Thus, HGF is a powerful angiogenic growth factor that 
is applicable for therapeutic purposes. 
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 The first clinical study of HGF gene therapy by naked expression plasmid was done to 
investigate its safety for the treatment of patients with arteriosclerosis obliterans or Buerger’s 
disease (57). Subsequently, a multicenter, randomized, double-blind, placebo-controlled 
clinical trial was performed for the treatment of patients with critical limb ischemia to evaluate 
the efficacy and safety of HGF gene therapy using naked plasmid (58, 59). This HGF gene 
therapy was proven safe and effective for critical limb ischemia. Phase-II and Phase-III clinical 
trials of HGF gene therapy for the treatment of peripheral arterial disease have been completed 
in the USA and in Japan, respectively.  
 
Hepatitis and acute kidney injury 
 Conditional Met gene disruption in hepatocytes has indicated that hepatocytes were highly 
susceptible to apoptosis even in mild injury, and the regenerative response in the liver was 
retarded when mice were subjected to liver injury. In preclinical models for fulminant hepatitis, 
systemic administration of recombinant HGF suppressed the onset of fulminant hepatitis (60). 
In a similar manner, conditional Met disruption in mature renal cells indicated mice had no 
appreciable defect in renal function, whereas they were susceptible to severe renal 
dysfunction and pathology when they were subjected to renal injury. In preclinical animal 
models for acute kidney injury, systemic administration of recombinant HGF suppressed 
tubular cell apoptosis and renal dysfunction, and promoted regenerative cell proliferation (7). 
HGF protein may be applicable to the treatment of patients with acute hepatitis or acute 
kidney injury. 
 The phase-I clinical trial of the systemic administration of recombinant HGF protein was 
completed in Japan and in the USA. Phase I/II clinical trials indicated that intravenous 
administration of HGF protein was well tolerated in patients with fulminant hepatitis (61). 
 
Amyotrophic lateral sclerosis (ALS) and spinal cord injury 
 ALS is a fatal neurodegenerative disease characterized by a progressive loss of motor 
neurons and a degeneration of motor axons. Approximately 5–10% of patients have familial 
ALS, and of those ~15–25% carry a mutation(s) in the gene encoding Cu2+/Zn2+ superoxide 
dismutase (SOD1). Neurons with a transgenic expression of mutant SOD1 develop the typical 
deficits found in both familial and sporadic ALS. Because motoneuronal degeneration is 
thought to be a primary event in disease progression, treatment approaches have focused on 
promoting the survival, or at least preventing the death, of motor neurons. In addition to 
motor neurons, since a reduction in the astrocyte-specific glutamate transporter has been 
found in ALS patients, astrocytes also seem to be potential targets for ALS therapy. 
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 HGF functions as a neurotrophic factor for a variety of neurons, including the hippocampal, 
cerebral cortical, midbrain dopaminergic, motor, sensory, sympathetic, parasympathetic, and 
cerebellar granule neurons (62). The first implication that HGF might be a therapeutic agent 
for the treatment of patients with ALS was obtained by transgenic over-expression of HGF in 
the nervous system in mouse model for ALS with mutant SOD1 (63). Neuronal 
overexpression of HGF has attenuated motor neuron death and axonal degeneration and 
prolonged the life span of ALS model mice. HGF expression maintained the levels of 
astrocyte-specific glutamate transporter in reactive astrocytes. HGF seems to alleviate the 
symptoms of ALS by reducing glutamatergic neurotoxicity through direct neurotrophic 
activities on motor neurons and indirect activities on astrocytes. 
 Human recombinant HGF was continuously administered by intrathecal delivery to 
transgenic rat models of ALS with mutant SOD1 at 100 days of age (pathologic changes, but 
animals showed no clinical weakness) and at 115 days (onset of paralysis) for 4 weeks each. 
Intrathecal administration of HGF attenuated motor neuron degeneration and prolonged the 
duration of the life span, even with administration from the onset of paralysis (64). The 
phase-I clinical trial for the intrathecal administration of recombinant HGF protein for 
treatment of patients with ALS has been conducted at the Tohoku University in Japan. 
 Spinal cord injury is followed by secondary degeneration, which is characterized by 
progressive tissue necrosis. Many therapeutic interventions using neurotrophic factors or 
pharmacological agents have focused on secondary degeneration after spinal cord injury to 
reduce damaged areas and promote axonal regeneration and functional recovery. The 
therapeutic action of recombinant HGF protein was tested in a primate (common marmoset) 
model of contusive cervical spinal cord injury (65). Intrathecal HGF administration preserved 
the intact spinal cord parenchyma, corticospinal fibers, and myelinated areas, thereby 
promoting functional recovery. HGF-treatment did not give rise to an abnormal outgrowth of 
calcitonin gene-related peptide positive fibers compared with that seen in the control group, 
indicating that this treatment neither induced nor exacerbated allodynia. The phase-I/II 
clinical trial for the intrathecal administration of recombinant human HGF protein for the 
treatment of patients with spinal cord injury is ongoing at the Keio University in Japan. 
 
Tumor Microenvironment and Drug Resistance 
 
Invasion and metastasis 
 The crucial role of stromal fibroblasts in the invasion of cancer cells through 3-D 
collagen was first demonstrated using human oral squamous cell carcinoma (66), suggesting 
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the important role of stromal cells in the dynamic invasion of cancer cells in a tumor 
microenvironment. Independently, as scatter factor, a fibroblast-derived cell motility factor for 
epithelial cells, is the same molecule to HGF (3), the migration and invasion of different types 
of cancer cells were markedly enhanced by HGF (67). HGF increases extracellular protease 
expression coupled with the dissociation of cancer cells and their motility, which promotes 
invasion in 3-D extracellular matrices and subsequent metastasis. HGF-Met signaling induces 
the transition of epithelial to mesenchymal cell types (68, 69). The profound action of HGF 
on cancer invasion has been demonstrated in a variety of cancer cells, and HGF has been 
established as an important mediator in the tumor-stromal interaction that affects the 
malignant behavior of cancer (67). Experimental activation of the HGF-Met pathway 
facilitates metastasis of different types of tumors, and aberrant activation of the HGF-Met 
pathway has been noted in a variety of human tumors (70, 71). The HGF-Met pathway has 
become a hot research and development target of molecular targeted therapy for cancer, 
particularly in attempts to inhibit cancer invasion and metastasis (72). 
 
Drug resistance 
 The discovery and application of oncoprotein-targeted drugs has improved cancer drug 
therapy. Mutationally activated protein kinases, particularly growth factor receptor tyrosine 
kinases and their downstream signaling kinases, define a clinically validated class of targets in 
the molecular targeted therapy of cancer. However, the efficacy of these inhibitors in patients 
whose tumors harbor mutated oncogenic protein is invariably limited by innate or acquired 
drug resistance. Elucidation of the mechanisms by which tumor cells acquire resistance to 
molecular targeted drugs both before and after treatment is now a very popular focus of 
research subject to overcome the theme of recurrence. 
 Gefitinib and erlotinib, selective inhibitors for EGFR tyrosine kinase, have shown 
favorable responses in non-small cell lung cancer (NSCLC), particularly those expressing 
activating mutations in EGFR (73, 74). Patients with EGFR mutant NSCLC had superior 
outcomes with gefitinib treatment, compared with standard first-line cytotoxic chemotherapy 
(75, 76). However, almost without exception, the patients developed acquired resistance to 
EGFR tyrosine kinase inhibitors within several years (77). Furthermore, 20–25% of the 
patients with EGFR-activating mutations showed intrinsic resistance to EGFR tyrosine kinase 
inhibitors.  
 Different mechanisms are known to participate in resistance to EGFR tyrosine kinase 
inhibitors in NSCLC with activating EGFR mutants. The T790M second mutation occurs in 
about half of all patients with acquired resistance to gefitinib or erlotinib (78). Involvement of 
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Met activation caused by the Met gene amplification (79) and HGF-dependent Met activation 
(80) have been noted as mechanisms by which NSCLC acquires resistance to EGFR tyrosine 
kinase inhibitors. Met gene amplification was detected in ~20% of patients with acquired 
resistance to gefitinib or erlotinib (81). Overexpression of HGF was detected in a population 
of specimens from EGFR mutant lung cancer patients who showed intrinsic or acquired 
resistance to EGFR tyrosine kinase inhibitors indicating the clinical relevance of this 
resistance mechanism in lung cancer (80−82). HGF can be produced by both cancer cells and 
host stromal cells, such as fibroblasts, within a tumor microenvironment. Collectively, the 
expression of HGF in cancer cells and/or host stromal cells closely participated in the 
resistance to EGFR tyrosine kinase inhibitors in NSCLC, even with Met gene amplification. 
 Malignant melanomas harboring a mutant BRAF gene encoding BRAF-V600E show 
marked responses to BRAF inhibitors. However, these responses are usually partial, and the 
tumors often recur within 6 months of treatment. Among growth factors, the importance of 
HGF in the tumor microenvironment to the innate or acquired resistance of tumor cells 
against BRAF inhibitor has been noted (83). That study was based on a hypothesis that the 
resistance to anticancer drugs might be influenced by the tumor microenvironment, and the 
growth/survival of a variety of tumor cells in the presence of anticancer drugs was compared 
for two conditions: when tumor cells were cultured alone or when tumor cells were 
co-cultured with a variety of stromal cells. A comprehensive analysis demonstrated a 
significant resistance of tumor cells conferred by the interaction with stromal cells. In 
particular, HGF was identified as a key factor that is secreted from stromal cells and confers 
resistance against BRAF inhibitors. Increases in the stromal expression of HGF in malignant 
melanoma tissues were correlated with a poor response to the BRAF inhibitor vemurafenib 
(83). 
 
Cancer stem cells 
 The concept of a cancer stem cell (or tumor initiating cell) proposes that tumors are 
organized in a cellular hierarchy, and they are maintained by a subpopulation of cells 
displaying stem cell characteristics such as self-renewal and differentiation that contributes to 
cellular heterogeneity and tumor bulk. The HGF-Met pathway plays an important role in 
regulating the self-renewal (stemness) and invasiveness of cancer stem cells (84−86). 
 Glioblastoma is an aggressive tumor that is associated with high morbidity, mortality, 
and recurrence. In a glioblastoma model, cancer stem cells aggressively invaded surrounding 
normal brain tissues, whereas tumor cells hierarchically descendant from tumor-initiating 
cells were not invasive and were located in the center of the tumor tissue (84). Microarray 
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analysis was used to analyze the difference in gene expression profiles between brain 
tumor-initiating cells and non-tumor-initiating cells. The results indicated that Met expression 
was much higher in tumor-initiating cells. It is important to note that strong in situ Met 
tyrosine phosphorylation was seen in the population of the cancer stem cells, but not in the 
population of their descendant cells. HGF enhanced invasion of the brain tumor-initiating 
cells in 3-D collagen gel culture. Extensive gene expression profiling study using the cultures 
of neurospheres obtained from patients with glioblastoma tissues indicated that in 
Met-positive neurospheres the subpopulation of cells that express high levels of Met display 
clonogenic potential and long-term self-renewal ability along with enhanced growth kinetics 
(85). HGF sustained the proliferation, clonogenicity, expression of self-renewal markers, 
migration, and invasion of Met-positive neurospheres. Thus, Met is likely to be a functional 
marker of glioblastoma stem cells. 
 Wnt/β-catenin signaling is crucial in maintaining stemness in normal colon cells and is 
a common pathway that is deregulated in most colon cancers. Despite the presence of 
mutations in APC or β-catenin, which are generally understood to constitutively activate the 
Wnt signaling cascade, colorectal cancers show cellular heterogeneity. In colon 
adenocarcinomas, high activity of the Wnt pathway was observed preferentially in tumor cells 
located close to stromal myofibroblasts, indicating that Wnt activity and cancer stemness 
might be regulated by extrinsic cues (86). Myofibroblast-derived factors, specifically HGF, 
activated Wnt/β-catenin signaling and subsequently the clonogenicity of colon cancer stem 
cells. Therefore, together with Wnt activity, HGF plays a role in maintaining the stemness of 
colon cancer stem cells through tumor-stromal interaction in the microenvironment. 
 
HGF-Met inhibitors in Clinical Development 
 
 Several distinct lines of approach to the inhibition of the HGF-Met pathway have been 
demonstrated, including small synthetic inhibitors of Met tyrosine kinase, ribozymes, small 
interfering RNA, monoclonal antibodies, soluble forms of Met, and antagonists composed of 
selected domains in HGF (e.g., NK4). Among them, only the development of small synthetic 
Met tyrosine kinase inhibitors and humanized monoclonal antibodies against HGF or Met has 
progressed to clinical trials. 
 Based on the wealth of accumulated knowledge gained from the success of the preclinical 
and clinical development of small synthetic tyrosine kinase inhibitors, several small synthetic 
Met tyrosine kinase inhibitors have entered clinical trials (Table 2). Crizotinib was originally 
developed as a Met tyrosine kinase inhibitor. It also strongly inhibits anaplastic lymphoma 
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kinase (ALK), which makes it a dual inhibitor for both ALK and Met (54). Crizotinib binds to 
a catalytic pocket in the tyrosine kinase domain of the Met in an ATP-competitive manner 
(54) (Fig. 3A). Because the fusion oncogene EML4-ALK has been effective for a distinct 
clinicopathologic subset of patients with non-small cell lung cancer, crizotinib has been 
approved for the treatment of the patients who harbor the EML4-ALK fusion gene. 
 The development of humanized antibody drugs, anti-HGF, and anti-Met antibodies have 
also entered the clinical trial stage. Onartuzumab is a monovalent mAb that binds to 
Sema-PSI domains in Met (Fig. 3B). The original bivalent monoclonal antibody was used for 
the subsequent discovery of onartumab bound to Met and exhibited agonistic action via 
receptor dimerization (16). Onartuzumab blocks the binding of HGF to Met and binds to Met 
without dimerization, thereby inhibiting HGF-dependent Met activation. Rilotumumab 
(AMG102) and ficlatuzumab (AV-229) are humanized monoclonal antibodies against HGF.
 Several small synthetic Met tyrosine kinase inhibitors are multi-target inhibitors, rather 
than monospecific inhibitors, while antibody drug candidates are monospecific. The 
characteristic of multi-target specificity may have an advantage in certain types of cancers 
wherein the co-activation of target kinases is an addictive key signal for their growth and 
survival. From past clinical experiences using small synthetic kinase inhibitors, resistant 
cancers appear within a certain period of time in most cases. Because mutations in the kinase 
domain structurally confer resistance to kinase inhibitors, the extracellular inhibition of 
HGF-Met protein-protein interaction by antibody drug candidates may have a potential 
advantage over small synthetic kinase inhibitors during the period marked by the emergence 
of resistant forms of cancer. The characteristics of the therapeutic effects from each of the 
HGF-Met inhibitors will be defined in further clinical trials. 
 
Artificial Small HGF 
 
 Cyclosporin A, originally isolated from the fungus Tolypocladim inflatum, is an 
orally-bioavailable immunosuppressant bears a highly modified peptide scaffold and its 
unique chemical characteristics confer drug-like properties, including affinity and specificity 
to target molecule and serum stability (resistance to proteases and peptidases). Novel 
technologies to identify peptides or peptide-like molecules have tremendous potential to 
revolutionize the speed of drug discovery. Random nonstandard Peptides Integrated 
Discovery (RaPID) system is originally developed as a novel technology to identify 
macrocyclic peptides that bind to target molecules with very high affinity and selectivity (87). 
 Very recent study identified macrocyclic peptide capable of activating Met (88). 
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Macrocyclic Met-binding peptides were identified using RaPID system. These peptides have 
neither activate Met nor inhibit HGF-induced Met activation. Dimerization of these peptides 
conferred them Met agonistic activity. Dimerized macrocyclic peptides selectively activate 
Met and exert Met-mediated typical and unique biological activities mitogenic, motogenic 
(enhancement of cell motility), and morphogenic (induction of blanching tubulogenesis) 
activities. The maximal activities of dimerized macrocyclic peptides are indistinguishable to 
HGF. Extracellular binding of the dimerized macrocyclic peptides to the Met induce 
dimerization of Met, and such structure in turn seems to give an appropriate length and/or 
angle for trans-phosphorylation of tyrosine residues between two tyrosine kinase domains 
(Fig. 4). The method taken in this study is adaptable to generate artificial “non-protein” 
growth factors structurally unrelated to its original protein. This work suggests alternative 




 After experimental partial hepatectomy in mice and rats, for which two-thirds of the liver 
is removed, the residual liver tissue enlarges to make up for the mass of the removed tissue 
within a week or so. This mysterious phenomenon has attracted much attention from scientists. 
Impaired regeneration of the liver has been noted in mice subjected to conditional knockout 
of certain types of genes, including the Met gene. By these approaches, our understanding of 
liver regeneration has definitively deepened. It is reasonable to assume that HGF plays a 
humoral hepatotrophic role in liver regeneration, which has been suggested by the results 
from early studies. Gene disruption approaches have defined irreplaceable roles for HGF in 
the regeneration, protection, and homeostasis of different tissues. As supplemental 
administration of bioactive peptides or cytokines has become indispensable in the treatment 
of certain types of diseases, the administration of HGF at the appropriate time and dose is 
expected to exhibit therapeutic action in patients with impaired tissue function. The dynamic 
and potent actions of HGF to promote cell movement, morphogenesis, and survival—the 
original functioning of tissue regeneration and protection—also closely participate in the 
malignant behaviors of tumors. Inhibition of the HGF-Met pathway has gained much 
attention in anticancer drug discovery, and HGF-Met inhibitors with different modes of action 
are either currently under clinical development or are already being marketed. Both basic and 
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Table 1. Physiological roles of HGF deduced from conditional knockout mice. 
 
 
Met-/- tissue/cell types characteristics references  
 
Liver 
 hepatocytes - highly susceptible to apoptosis after liver injury 26 
  - impairment in recovery from liver necrosis after liver injury 
  - impairment in Erk1/2 activation and G2/M transition after liver injury 27 
 
 hepatocytes - steatotic change of the liver in aged mice 28 
  - decrease in mitotic hepatocytes after partial hepatectomy 
  - delayed regeneration after partial hepatectomy 
 
 hepatocytes - promoted liver fibrosis after liver injury 29 
  - extensive necrosis and lower proliferation of hepatocytes after 30 
     bile-duct ligation 
  - enhanced susceptibility to liver fibrosis 
 
 oval cells - decrease in oval cell viability 31 
  - more prone to apoptosis 
  - reduction in oval cell pool  32 
  - impairment in migration and differentiation into hepatocytes 
 
Kidney 
 tubular cells - no appreciable defect in kidney morphology and function 33 
  - aggravated renal injury and inflammation after acute kidney injury 
 podocytes - neither albuminuria nor overt pathologic lesions 34 
  - severe podocyte injury and apoptosis, and albuminuria after toxic injury 
 collecting duct - increased fibrosis and tubular necrosis after unilateral ureteral obstruction 35 
  - reduced capacity in regeneration after release of the obstruction 
 ureteric bud - double knockout of Met and EGF receptor in ureteric bud 36 
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  - decrease in branching and a reduction in final glomerular number  
 
Skin 
 keratinocytes - lack of keratinocyte migration after skin wound 37 
  - severe impairment epidermal wound closure 
 
Pancreas 
 β-cell - mild hyperglycemia, and decreased serum insulin levels at 6 months 38 
  - loss of acute-phase insulin secretion in response to glucose  
  - impaired glucose tolerance 
  - diminished glucose tolerance 39 
  - reduced plasma insulin after a glucose challenge 
  - normal glucose and β-cell homeostasis 40 
  - susceptible to streptozotocin-induced diabetes 
 
Nervous 
 dorsal pallial - increases proximal and reduces distal apical dendritic branching of  41 
 forebrain neurons   neocortical pyramidal neurons in post-pubertal period 
  - reduced volume of cortical tissue 
  - increase in spine head volume, but no change in density of spines 
  - hyperconnectivity in circuit-specific intracortical neurons 42 
 
Heart 
 cardiomyocytes - normal heart development 43 
  - cardiomyocyte hypertrophy and interstitial fibrosis by 6 months 
  - systolic cardiac dysfunction by 9 months 
 
Immune system 
 dendritic cells - impaired emigration toward draining lymph nodes upon  44 
      inflammation-induced activation 
  - impaired contact hypersensitivity reaction to contact allergens 
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Table 2. HGF-Met inhibitors in clinical development* 
 
 




AMG 208 Met phase-I advanced solid tumors 
 
BMS-777607 Met phase-I/II advanced/metastatic gastroesophageal cancer, 
   head and neck squamous cell carcinoma, 
   type I papillary renal cell carcinoma 
 
E7050 Met, VEGFR2 phase-II advanced solid tumors, recurrent glioblastoma, 
   unresectable stage III/IV melanoma 
 
Foretinib Met, Ron, VEGFR1-3, phase-II head and neck recurrent/metastatic squamous cell carcinoma, 
(GSK1363089) PDGFR, Kit, Flt-3, Tie-2  advanced/metastatic gastric cancer 
  phase-I/II HER2-positive metastatic breast cancer 
 
Amuvatinib Met, Ret, Kit, PDGFR, Flt-3 phase-II small cell lung cancer 
(MP470) 
 
MGCD265 Met  phase-I advanced malignancies, non-small cell lung cancer 
 
MK-2461 Met, Tie-2, Ron phase-I/II advanced solid malignancies 
 
Crizotinib  Alk, Met phase-II stage III non-small cell lung cancer, 
(PF-02341066)   advanced and/or metastatic type I papillary renal cell carcinoma, 
   advanced and/or metastatic large cell lymphoma, etc. 
  phase-I/II relapsed/refractory solid malignancies 
  approved Alk-mutated non-small cell lung cancer 
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Cabozantinib  Met, VEGFR1-3, Ret, Kit, phase-I metastatic colorectal cancer (KRAS wild type) 
(XL184) Flt-3, Tie-2 phase-II glioblastoma multiforme, plexiform neutofibromatosis, 
   advanced chollangiocarcinoma, 
   carcinoid/pancreatic neuroendocrine tumor, 
   metastatic castrate-resistant prostate cancer, 
   non-small cell lung cancer, metastatic endometrial cancer 
  phase-III  hepatocellular carcinoma 
  approved progressive metastatic medullary thyroid cancer 
 
Antibody 
Rilotumumab  HGF phase-I/II advanced malignant glioma, prostate cancer, 
(AMG102)   metastatic gastric and esophageal adenocarcinoma 
  phase-II advanced gastroesophageal adenocarcinoma, 
   advanced malignant glioma, advanced renal cell carcinoma 
  phase-II/III non-small cell lung cancer 
  phase-III gastroesophageal junction adenocarcinoma, gastric cancer 
 
Onartuzumab Met phase-I advanced hepatocellular carcinoma 
  phase-II non-small cell lung cancer, metastatic colorectal cancer 
  phase-III advanced and/or metastatic non-small cell lung cancer, 
   metastatic gastroesophageal cancer 
 
Ficlatuzumab HGF phase-I head and neck squamous cell carcinoma 
(AV-229)  phase-II non-small cell lung cancer 
 




Fig. 1. Two-pronged roles of HGF. Dynamic blanching morphogenesis (e.g., in renal tubular 
cells) and promotion of cell survival (e.g., in neurons) mediated by the HGF–Met pathway 
play roles in tissue regeneration and protection after injury (right part). In tumor tissues, 
however, similar biological activities, i.e., dynamic cell movement and survival, promoted by 
Met activation also participate in invasion-metastasis and drug resistance (left part). Cells 
responding to HGF are conceptually shown in green. 
 
Fig. 2. Structural basis for HGF-Met interactions and Met activation. (A) Outline structures of 
HGF (left) and extracellular interaction between HGF and Met (right). The outline structure 
for extracellular interaction between HGF and Met was proposed by analysis using 
small-angle x-ray scattering and cryoelectron microscopy (12). (B) Crystal structure for 
association between the β-chain of HGF and Sema-PSI domains in the Met (16) (PDB: 4K3J). 
(C) Crystal structure for Met tyrosine kinase and a part of the juxtamembrane domain (17, 18) 
(PDB: 1R0P and 2G15). In the ribbon drawing (upper), structural change of the activation 
loop occurs between the active status and inactive status shown in red and blue, respectively. 
Structural change in the catalytic hollow for tyrosine kinase is shown in the surface drawing 
(lower). 
 
Fig. 3. Structural basis for HGF-Met inhibitors in clinical development. (A) Crystal structure 
for binding of crizotinib (PF-02341066), a dual tyrosine kinase inhibitor for Alk and Met, in 
the Met tyrosine kinase domain (54) (PDB: 2WGJ). (B) Crystal structure for association 
between Sema-PSI domains of Met and onartumab, a monovalent monoclonal antibody 
against Met (16) (PDB: 4K3J). Comparison of structures for association between Sema-PSI 
domains and the β-chain of HGF (Fig. 2B) or onartumab indicate onartumab and the β-chain 
of HGF bind to opposite positions in Met. 
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